These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 19714737)
1. Sample-size calculations for multi-group comparison in population pharmacokinetic experiments. Ogungbenro K; Aarons L Pharm Stat; 2010; 9(4):255-68. PubMed ID: 19714737 [TBL] [Abstract][Full Text] [Related]
2. Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments. Ogungbenro K; Aarons L; Graham G J Biopharm Stat; 2006; 16(2):135-50. PubMed ID: 16584063 [TBL] [Abstract][Full Text] [Related]
3. Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations. Ogungbenro K; Aarons L J Biopharm Stat; 2008; 18(6):1212-27. PubMed ID: 18991118 [TBL] [Abstract][Full Text] [Related]
4. Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements. Ogungbenro K; Aarons L J Biopharm Stat; 2010 Sep; 20(5):1026-42. PubMed ID: 20721789 [TBL] [Abstract][Full Text] [Related]
5. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Steimer JL; Mallet A; Golmard JL; Boisvieux JF Drug Metab Rev; 1984; 15(1-2):265-92. PubMed ID: 6745083 [TBL] [Abstract][Full Text] [Related]
6. On design considerations and randomization-based inference for community intervention trials. Gail MH; Mark SD; Carroll RJ; Green SB; Pee D Stat Med; 1996 Jun; 15(11):1069-92. PubMed ID: 8804140 [TBL] [Abstract][Full Text] [Related]
8. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies. Foo LK; McGree J; Duffull S Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749 [TBL] [Abstract][Full Text] [Related]
9. Sample size/power calculations for repeated ordinal measurements in population pharmacodynamic experiments. Ogungbenro K; Aarons L J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):67-83. PubMed ID: 19967433 [TBL] [Abstract][Full Text] [Related]
10. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371 [TBL] [Abstract][Full Text] [Related]
12. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. Zhou H; Mayer PR; Wajdula J; Fatenejad S J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641 [TBL] [Abstract][Full Text] [Related]
13. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments. Ogungbenro K; Aarons L J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474 [TBL] [Abstract][Full Text] [Related]
14. Sampling strategies for occupational exposure assessment under generalized linear model. Chen CC; Chuang CL; Wu KY; Chan CC Ann Occup Hyg; 2009 Jul; 53(5):509-21. PubMed ID: 19460758 [TBL] [Abstract][Full Text] [Related]